正式舞会
判别效度
医学
患者报告的结果
结构效度
前瞻性队列研究
物理疗法
急性胰腺炎
可解释性
标准效度
比例(比率)
生活质量(医疗保健)
可靠性(半导体)
队列
队列研究
公制(单位)
外科
内科学
患者满意度
内部一致性
机器学习
计算机科学
护理部
功率(物理)
经济
产科
物理
量子力学
运营管理
作者
Enrique de‐Madaria,Claudia Sánchez‐Marin,Irene Carrillo,Santhi Swaroop Vege,S. Chooklin,Andriy Bilyak,Rafael Mejuto,Violeta Mauriz,Péter Hegyi,Katalin Márta,Ayesha Kamal,Eugenia Lauret-Braña,Sorin T. Barbu,Vítor Nunes,María Lourdes Ruiz-Rebollo,Guillermo García‐Rayado,Edgard Efrén Lozada Hernández,Jorge Pereira,Ionuț Negoi,Silvia Espina
出处
期刊:Gut
[BMJ]
日期:2020-04-03
卷期号:70 (1): 139-147
被引量:43
标识
DOI:10.1136/gutjnl-2020-320729
摘要
Objective This study aimed to develop and validate a patient-reported outcome measure (PROM) in acute pancreatitis (AP) as an endpoint centred on the patient. Design A PROM instrument (PAtieNt-rePoRted OutcoMe scale in acute pancreatItis, an international proSpEctive cohort study, PAN-PROMISE scale) was designed based on the opinion of patients, professionals and an expert panel. The scale was validated in an international multicentre prospective cohort study, describing the severity of AP and quality of life at 15 days after discharge as the main variables for validation. The COSMIN (COnsensus-based Standards for the selection of health status Measurement INstruments) methodology was applied. Both the design and validation stages considered the content and face validity of this new instrument; the metric properties of the different items, reliability (reproducibility and internal consistence), the construct, structural and criterion validity, responsiveness and interpretability of this scale. Results PAN-PROMISE consists of a seven-item scale based on the symptoms that cause the most discomfort and concern to patients with AP. The validation cohort involved 15 countries, 524 patients. The intensity of symptoms changed from higher values during the first 24 hours to lower values at discharge and 15 days thereafter. Items converged into a unidimensional ordinal scale with good fit indices. Internal consistency and split-half reliability at discharge were adequate. Reproducibility was confirmed using test–retest reliability and comparing the PAN-PROMISE score at discharge and 15 days after discharge. Evidence is also provided for the convergent-discriminant and empirical validity of the scale. Conclusion The PAN-PROMISE scale is a useful tool to be used as an endpoint in clinical trials, and to quantify patient well-being during the hospital admission and follow-up. Trial registration number NCT03650062
科研通智能强力驱动
Strongly Powered by AbleSci AI